This report provides comprehensive information on the therapeutic development for Alzheimer's Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Alzheimer's Disease and special features on late-stage and discontinued projects.

1. Alzheimers Disease - Pipeline Review, H1 2014
Global Markets Direct’s, ‘Alzheimer's Disease - Pipeline Review, H1 2014’, provides an overview of the Alzheimer's Disease’s
therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Alzheimer's Disease, complete with comparative analysis at various stages,
therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured
news and press releases. It also reviews key players involved in the therapeutic development for Alzheimer's Disease and special features on late-stage and
discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is
built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor
presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s
team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated
with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking
ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by
identifying new targets and MOAs to produce first-in-class and best-in-class products.
Scope
The report provides a snapshot of the global therapeutic landscape of Alzheimer's Disease The report reviews key pipeline products under drug profile section
which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities The report reviews key players
involved in the therapeutics development for Alzheimer's Disease and enlists all their major and minor projects The report summarizes all the dormant and
discontinued pipeline projects A review of the Alzheimer's Disease products under development by companies and universities/research institutes based on
information derived from company and industry-specific sources Pipeline products coverage based on various stages of development ranging from
pre-registration till discovery and undisclosed stages A detailed assessment of monotherapy and combination therapy pipeline projects Coverage of the
Alzheimer's Disease pipeline on the basis of target, MoA, route of administration and molecule type Latest news and deals relating related to pipeline products
Reasons to buy
Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies Identify emerging players
with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage Develop strategic initiatives by understanding the
focus areas of leading companies Identify and understand important and diverse types of therapeutics under development for Alzheimer's Disease Plan mergers
and acquisitions effectively by identifying key players of the most promising pipeline Devise corrective measures for pipeline projects by understanding
Alzheimer's Disease pipeline depth and focus of Indication therapeutics Develop and design in-licensing and out-licensing strategies by identifying prospective
partners with the most attractive projects to enhance and expand business potential and scope Modify the therapeutic portfolio by identifying discontinued
projects and understanding the factors that drove them from pipeline
table Of Content
introduction
alzheimer's Disease Overview
therapeutics Development
alzheimer's Disease - Therapeutics Under Development By Companies
alzheimer's Disease - Therapeutics Under Investigation By Universities/institutes
alzheimer's Disease - Pipeline Products Glance
alzheimer's Disease - Products Under Development By Companies
alzheimer's Disease - Products Under Investigation By Universities/institutes
alzheimer's Disease - Companies Involved In Therapeutics Development
alzheimer's Disease - Therapeutics Assessment
drug Profiles
alzheimer's Disease - Recent Pipeline Updates
alzheimer's Disease - Dormant Projects
alzheimer's Disease - Discontinued Products
alzheimer's Disease - Product Development Milestones
appendix
ResearchMoz(http://www.researchmoz.us/) is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your
research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and
across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an
informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.
Contact:
M/s Sheela,
90 State Street,
Suite 700,
Albany NY - 12207
United States
Alzheimers Disease - Pipeline Review, H1 2014

2. Tel: +1-518-618-1030
USA - Canada Toll Free 866-997-4948
Email: sales@researchmoz.us
Website: http://www.researchmoz.us/
Alzheimers Disease - Pipeline Review, H1 2014